The U.S. Food and Drug Administration approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).
The U.S. Food and Drug Administration greenlit Xipere, the first suprachoroidal injectable medicine for macular edema associated with uveitis, co-developed by Clearside Biomedical and Bausch & Lomb.
Biogen reported that the company’s gene therapy, cotoretigene toliparvovec, failed to hit the primary endpoint of the Phase II/III XIRIUS trial for X-linked retinitis pigmentosa (XLRP).
Roche announced topline data from two identical Phase III trials (TENAYA and LUCERNE) of faricimab in neovascular or “wet” age-related macular degeneration (nAMD), with both studies hitting their primary endpoint.
Microsoft announced AI for Health, a new $40 million program which is part of the AI for Good initiative that will leverage artificial intelligence technology to “empower researchers and organizations addressing some of the world’s toughest challenges in health.”
Novartis received approval from the U.S. Food and Drug Administration for the Swiss pharmaceuticals company’s drug Beovu to treat a cause of vision loss.
Paris-based GenSight Biologics reported the first group of data from Week 96 of the company’s RESCUE Phase III clinical trial.
The U.S. FDA approved Regeneron Pharmaceuticals Inc.’s Eylea (aflibercept) Injection for all stages of diabetic retinopathy, which is the leading cause of vision loss in diabetic patients.